Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

Tino F. Schwarz, Mariële Kocken, Tiina Petäjä, Mark H. Einstein, Marek Spaczynski, Jacqueline A. Louwers, Court Pedersen, Myron Levin, Toufik Zahaf, Sylviane Poncelet, Karin Hardt, Dominique Descamps, Gary Dubin

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

This pooled analysis of data from four Phase III clinical trials was undertaken to assess the correlation between levels of anti-human papillomavirus (HPV)-16/18 antibodies in serum and cervicovaginal secretions (CVS) in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine. Serum and CVS samples were collected from a subset of women aged 10-65 years (N = 350) at pre-specified time-points from 7 to 36 months post-vaccination. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay. Pearson correlation coefficients between serum and CVS antibody levels, standardized for total immunoglobulin G, were calculated at each time-point in women with detectable antibodies in both serum and CVS. All subjects had seroconverted at Month 7 and remained seropositive through Month 36 for both antigens. Geometric mean titers of anti-HPV-16/18 antibodies in serum were substantially higher at all time-points than those in a control group of women who had cleared a natural HPV infection in another trial. In women with detectable antibodies in both serum and CVS, good correlation was seen between HPV-16/18 antibody levels at all time-points (Pearson correlation coefficient: 0.84-0.92 for HPV-16 and 0.90-0.91 for HPV-18). The strong correlation between levels of HPV-16/18 antibodies in serum and CVS up to 36 months post-vaccination in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine supports transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. These CVS antibodies may play a role in the protective efficacy of this vaccine.

Original languageEnglish (US)
Pages (from-to)1054-1061
Number of pages8
JournalHuman Vaccines
Volume6
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Vaccines
Antibodies
Serum
Vaccination
Phase III Clinical Trials
Papillomavirus Infections
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay

Keywords

  • Cervicovaginal secretions
  • HPV
  • HPV-16/18 AS04-adjuvanted vaccine
  • Human papillomavirus
  • Prophylactic HPV vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. / Schwarz, Tino F.; Kocken, Mariële; Petäjä, Tiina; Einstein, Mark H.; Spaczynski, Marek; Louwers, Jacqueline A.; Pedersen, Court; Levin, Myron; Zahaf, Toufik; Poncelet, Sylviane; Hardt, Karin; Descamps, Dominique; Dubin, Gary.

In: Human Vaccines, Vol. 6, No. 12, 12.2010, p. 1054-1061.

Research output: Contribution to journalArticle

Schwarz, TF, Kocken, M, Petäjä, T, Einstein, MH, Spaczynski, M, Louwers, JA, Pedersen, C, Levin, M, Zahaf, T, Poncelet, S, Hardt, K, Descamps, D & Dubin, G 2010, 'Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine', Human Vaccines, vol. 6, no. 12, pp. 1054-1061. https://doi.org/10.4161/hv.6.12.13399
Schwarz, Tino F. ; Kocken, Mariële ; Petäjä, Tiina ; Einstein, Mark H. ; Spaczynski, Marek ; Louwers, Jacqueline A. ; Pedersen, Court ; Levin, Myron ; Zahaf, Toufik ; Poncelet, Sylviane ; Hardt, Karin ; Descamps, Dominique ; Dubin, Gary. / Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. In: Human Vaccines. 2010 ; Vol. 6, No. 12. pp. 1054-1061.
@article{663643f72007421987fef1583c7519d6,
title = "Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine",
abstract = "This pooled analysis of data from four Phase III clinical trials was undertaken to assess the correlation between levels of anti-human papillomavirus (HPV)-16/18 antibodies in serum and cervicovaginal secretions (CVS) in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine. Serum and CVS samples were collected from a subset of women aged 10-65 years (N = 350) at pre-specified time-points from 7 to 36 months post-vaccination. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay. Pearson correlation coefficients between serum and CVS antibody levels, standardized for total immunoglobulin G, were calculated at each time-point in women with detectable antibodies in both serum and CVS. All subjects had seroconverted at Month 7 and remained seropositive through Month 36 for both antigens. Geometric mean titers of anti-HPV-16/18 antibodies in serum were substantially higher at all time-points than those in a control group of women who had cleared a natural HPV infection in another trial. In women with detectable antibodies in both serum and CVS, good correlation was seen between HPV-16/18 antibody levels at all time-points (Pearson correlation coefficient: 0.84-0.92 for HPV-16 and 0.90-0.91 for HPV-18). The strong correlation between levels of HPV-16/18 antibodies in serum and CVS up to 36 months post-vaccination in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine supports transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. These CVS antibodies may play a role in the protective efficacy of this vaccine.",
keywords = "Cervicovaginal secretions, HPV, HPV-16/18 AS04-adjuvanted vaccine, Human papillomavirus, Prophylactic HPV vaccines",
author = "Schwarz, {Tino F.} and Mari{\"e}le Kocken and Tiina Pet{\"a}j{\"a} and Einstein, {Mark H.} and Marek Spaczynski and Louwers, {Jacqueline A.} and Court Pedersen and Myron Levin and Toufik Zahaf and Sylviane Poncelet and Karin Hardt and Dominique Descamps and Gary Dubin",
year = "2010",
month = "12",
doi = "10.4161/hv.6.12.13399",
language = "English (US)",
volume = "6",
pages = "1054--1061",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine

AU - Schwarz, Tino F.

AU - Kocken, Mariële

AU - Petäjä, Tiina

AU - Einstein, Mark H.

AU - Spaczynski, Marek

AU - Louwers, Jacqueline A.

AU - Pedersen, Court

AU - Levin, Myron

AU - Zahaf, Toufik

AU - Poncelet, Sylviane

AU - Hardt, Karin

AU - Descamps, Dominique

AU - Dubin, Gary

PY - 2010/12

Y1 - 2010/12

N2 - This pooled analysis of data from four Phase III clinical trials was undertaken to assess the correlation between levels of anti-human papillomavirus (HPV)-16/18 antibodies in serum and cervicovaginal secretions (CVS) in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine. Serum and CVS samples were collected from a subset of women aged 10-65 years (N = 350) at pre-specified time-points from 7 to 36 months post-vaccination. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay. Pearson correlation coefficients between serum and CVS antibody levels, standardized for total immunoglobulin G, were calculated at each time-point in women with detectable antibodies in both serum and CVS. All subjects had seroconverted at Month 7 and remained seropositive through Month 36 for both antigens. Geometric mean titers of anti-HPV-16/18 antibodies in serum were substantially higher at all time-points than those in a control group of women who had cleared a natural HPV infection in another trial. In women with detectable antibodies in both serum and CVS, good correlation was seen between HPV-16/18 antibody levels at all time-points (Pearson correlation coefficient: 0.84-0.92 for HPV-16 and 0.90-0.91 for HPV-18). The strong correlation between levels of HPV-16/18 antibodies in serum and CVS up to 36 months post-vaccination in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine supports transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. These CVS antibodies may play a role in the protective efficacy of this vaccine.

AB - This pooled analysis of data from four Phase III clinical trials was undertaken to assess the correlation between levels of anti-human papillomavirus (HPV)-16/18 antibodies in serum and cervicovaginal secretions (CVS) in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine. Serum and CVS samples were collected from a subset of women aged 10-65 years (N = 350) at pre-specified time-points from 7 to 36 months post-vaccination. Anti-HPV-16/18 antibody levels in serum and CVS were measured by enzyme-linked immunosorbent assay. Pearson correlation coefficients between serum and CVS antibody levels, standardized for total immunoglobulin G, were calculated at each time-point in women with detectable antibodies in both serum and CVS. All subjects had seroconverted at Month 7 and remained seropositive through Month 36 for both antigens. Geometric mean titers of anti-HPV-16/18 antibodies in serum were substantially higher at all time-points than those in a control group of women who had cleared a natural HPV infection in another trial. In women with detectable antibodies in both serum and CVS, good correlation was seen between HPV-16/18 antibody levels at all time-points (Pearson correlation coefficient: 0.84-0.92 for HPV-16 and 0.90-0.91 for HPV-18). The strong correlation between levels of HPV-16/18 antibodies in serum and CVS up to 36 months post-vaccination in girls and women vaccinated with the HPV-16/18 AS 04-adjuvanted vaccine supports transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. These CVS antibodies may play a role in the protective efficacy of this vaccine.

KW - Cervicovaginal secretions

KW - HPV

KW - HPV-16/18 AS04-adjuvanted vaccine

KW - Human papillomavirus

KW - Prophylactic HPV vaccines

UR - http://www.scopus.com/inward/record.url?scp=78751677213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751677213&partnerID=8YFLogxK

U2 - 10.4161/hv.6.12.13399

DO - 10.4161/hv.6.12.13399

M3 - Article

C2 - 21157180

AN - SCOPUS:78751677213

VL - 6

SP - 1054

EP - 1061

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 12

ER -